HighTower Advisors’s Krystal Biotech KRYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$796K Buy
2,394
+265
+12% +$91.8K ﹤0.01% 2413
2026
Q2
$791K Buy
2,129
+80
+4% +$23.9K ﹤0.01% 2387
2026
Q1
$529K Buy
2,049
+937
+84% +$249K ﹤0.01% 2668
2025
Q4
$274K Buy
+1,112
New +$234K ﹤0.01% 3116

Other funds holding KRYS

HighTower Advisors's KRYS Position: Q3 2026 in Review

HighTower Advisors increased its Krystal Biotech (KRYS) stake by 12% in Q3 2026, buying an estimated $91.8K and bringing the position to 2,394 shares worth $796K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

HighTower Advisors first reported a position in KRYS in Q4 2025 and has held it in 4 quarters since. 388 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • HighTower Advisors held 2,394 shares of Krystal Biotech worth $796K as of Q3 2026.
  • HighTower Advisors bought 265 Krystal Biotech shares in Q3 2026, an estimated $91.8K.
  • Krystal Biotech made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #2413 holding.
  • HighTower Advisors first reported a position in Krystal Biotech in Q4 2025 and has held it in 4 quarters since.
  • 388 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.